Business Wire

H.I.G.-WHITEHORSE-EUROPE

26.3.2024 14:31:32 CET | Business Wire | Press release

Share
H.I.G. WhiteHorse Europe Finances Stordata

H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a financing package for Stordata (the “Company”).

Founded in 1988, and headquartered in Versailles, France, Stordata has established itself as a reference partner for the digital transformation of mid-size and large companies, with around 500 clients. An expert in architecture, administration, and maintenance of security and data management systems, particularly in the cloud, the Company provides critical continuous access services to its clients. The services allow clients to leverage their data in a complex and constantly evolving IT environment. The Company has experienced sustained growth in recent years and is developing additional service offerings around cybersecurity and cloud services.

Stordata is embarking on a new chapter in its development through the acquisition of a majority stake by funds advised by Elyan Partners (“Elyan”), a member of the Edmond de Rothschild Private Equity partnership from the founders and executives of the Company, who are reinvesting in the Company.

H.I.G. WhiteHorse Europe has arranged a bespoke financing package, which will be used to finance the acquisition and provide additional capital to support the Company’s expansion, especially through an active buy-and-build strategy.

H.I.G. WhiteHorse Europe, through some of its affiliates, acted as the sole arranger, while Caisse d’Epargne et de Prévoyance Hauts de France participated in the financing alongside H.I.G. WhiteHorse.

Marc Michel, Co-Founder, and Olivier Teichman, CEO of Stordata, said: “Stordata’s success is built on the technical expertise of our employees, the quality of service delivered to our clients, and the trust placed in us by our technology partners. We are so grateful for their continued support. We are also excited by our new partnership with Elyan and appreciative of the confidence we received from H.I.G. WhiteHorse and Caisse d’Epargne et de Prévoyance Hauts de France. We believe Stordata is poised for a robust growth phase.”

Jeremie Melin and Vincent Manes, Partners at Elyan said: “We have been impressed by what Stordata has built over the past years. We are convinced that it can be the foundation of an ambitious growth in France and in Europe, to offer even more value and expertise to Stordata’s clients, particularly in cybersecurity and in the cloud. With H.I.G. WhiteHorse and Caisse d’Epargne et de Prévoyance Hauts de France, we believe we have the right like-minded partners who understand the business and share common values and vision.”

Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said: “Stordata has embarked on a remarkable growth journey in recent years, leveraging its expertise in security and data management, further reinforcing its position in the French digital transformation sector. We are excited to partner with a very experienced investor in Elyan and to contribute to the future success of the Company via a tailor-made financing.”

Charles Bourgeois, Managing Director at H.I.G. WhiteHorse Europe, said: “We are delighted to support Stordata and Elyan. We have been impressed by Stordata’s very high level of expertise and by the quality of its management team. Stordata's strong market reputation and significant market share have firmly established the company as the market leader among mid- and large-size clients.”

About Stordata

Stordata is an independent expert in data and virtualization, combining consulting, transformation management, administration, and maintenance of data security and management systems. Its cloud offering (StorCloud) is ISO27001 and HDS (Hébergeurs de Données de Santé - Health Data Hosts) certified.

About H.I.G. Capital

H.I.G. Capital is a leading global alternative investment firm with $60 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/ value-added approach:

  • H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  • H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
  • H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
  • H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.

About Elyan Partners & ERES IV

Elyan Partners SAS is a financial investment advisor and partner of Edmond de Rothschild Private Equity. Elyan is the exclusive advisor to the ERES funds and an advisor to the Privilege funds of the Edmond de Rothschild Group. Edmond de Rothschild Equity Strategies IV SLP (“ERES IV”) invests in medium-sized companies in Europe and North America.

Edmond de Rothschild Private Equity is the trade name of the Edmond de Rothschild Group’s private equity entities and has over CHF 3.6 billion of assets under management. Founded in 1953, the Group had nearly CHF 158 billion in assets under management as of 31 December 2022, 2,500 employees, and 30 offices worldwide.

*Based on total capital raised by H.I.G. Capital and affiliates.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240326501486/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye